Vanguard Group Inc. Has $587.12 Million Stake in Roivant Sciences Ltd. $ROIV

Vanguard Group Inc. cut its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 38,804,928 shares of the company’s stock after selling 521,408 shares during the period. Vanguard Group Inc. owned approximately 5.68% of Roivant Sciences worth $587,119,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in ROIV. Jones Financial Companies Lllp boosted its position in shares of Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares in the last quarter. Bessemer Group Inc. lifted its position in shares of Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. CWM LLC boosted its stake in Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after acquiring an additional 920 shares in the last quarter. Osaic Holdings Inc. boosted its stake in Roivant Sciences by 204.2% during the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock worth $65,000 after acquiring an additional 3,882 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in Roivant Sciences by 16.6% in the third quarter. GAMMA Investing LLC now owns 9,302 shares of the company’s stock worth $141,000 after purchasing an additional 1,324 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Trading Up 1.8%

NASDAQ:ROIV opened at $28.26 on Wednesday. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $28.29. The company has a 50 day simple moving average of $23.54 and a two-hundred day simple moving average of $19.19. The company has a market cap of $20.23 billion, a PE ratio of -24.15 and a beta of 1.22.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 339,441 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $26.47, for a total transaction of $8,985,003.27. Following the transaction, the insider directly owned 19,148,664 shares in the company, valued at $506,865,136.08. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the sale, the chief executive officer directly owned 1,654,597 shares in the company, valued at $43,830,274.53. This represents a 10.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,318,014 shares of company stock worth $315,727,023 over the last 90 days. 10.80% of the stock is owned by insiders.

More Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Several brokerages have raised price targets and maintained buy ratings (Goldman Sachs, HC Wainwright, Citi among them), and the street consensus is a “Moderate Buy” — a catalyst supporting demand for the shares. Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Institutional ownership is substantial (~65%) and recent filings show new and increased positions by several funds — this can sustain liquidity and limit extreme volatility but also means moves can be driven by fund flows. ROIV Stock Profile and Institutional Trading (MarketBeat)
• Negative Sentiment: Frank Torti sold roughly 3.0M shares across Feb. 19–23 for about $82M in aggregate (multiple Form 4 filings), trimming his stake — a sizable insider disposition that can create downward pressure or signal owner liquidity needs. Frank Torti Sells 587,390 Shares of Roivant Sciences (NASDAQ:ROIV) Stock Un initié de Roivant Sciences cède des actions pour une valeur de 82 039 460 $, selon un récent dépôt à la SEC

Analyst Ratings Changes

Several analysts have recently commented on the company. Citigroup raised their target price on Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. HC Wainwright raised their price objective on Roivant Sciences from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Weiss Ratings downgraded shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Roivant Sciences in a research note on Monday, February 9th. Finally, Leerink Partners raised their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Roivant Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $28.69.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.